NCT05304351: An ongoing trial by Curevo Inc
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05304351 |
|---|---|
| Title | A Randomized, Observer-Blind, Phase 2 Study To Assess the Safety and Immunogenicity of CRV-101 Vaccine Head-To-Head With SHINGRIX® for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 2, 2022 |
| Completion date | June 30, 2026 |
| Required reporting date | June 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |